Clinical Trials Logo

Clinical Trial Summary

Diabetic nephropathy is one of the most feared complications of Diabetes Mellitus type 2, characterized mainly by the decrease in the glomerular filtration rate and an increase in protein secretion by the kidney, that results in proteinuria. This has led to the development of intensive treatment regimens for patients with diabetes and preventive measures since once the complications have already presented the improvement of glycemic control alone may not be enough, to prevent the progression of pathological processes. Currently, interventions to delay the progression of kidney damage, include changes in lifestyle, nutritional advice and regular exercise, achieve optimal levels in glycemic control and use of pharmacological therapies with nephroprotector, angiotensin II receptor blocker (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs). The most important biochemical mechanism proposed for this progression is the excessive binding of glucose to proteins, better described as the final products of advanced glycosylation (AGEs); the interaction of AGEs with its receptor (RAGE), participates in the metabolic and biochemical pathways in intracellular signaling, either by favoring or aggravating cell nephron damage. Recently, numerous RAGE isoforms have been described as: soluble RAGE, which are devoid of cytoplasmic domains, which bind to ligands that include AGEs and can antagonize intracellular signaling. Therefore, the need to seek for alternative therapies like nutraceuticals is arising, mainly due to its low toxicity and lower cost. Such is the case of green tea extract, which due to its chemical composition, especially of flavonoids that generate antioxidant and anti-inflammatory effects, In vivo and in clinical trials have shown that it could impact the progression of the diabetic neuropathy , through the modulation of the biological process, including molecular and biochemical pathways such as release of soluble RAGE.


Clinical Trial Description

The objective of the study is to evaluate the effect of the administration of green tea extract on soluble RAGE and renal damage in patients with Type 2 Diabetes Mellitus, by means of a clinical trial, double blind, with randomization and placebo control group. In male and female population, with a diagnosis of Diabetes Mellitus type 2, under treatment with hypoglycemic agents and / or insulin and kidney damage, 2 - 3a grade according to classification of the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines and HbA1c levels 9 - 12% who sign the letter of consent under information, from 35 to 65 years of age, residents of the metropolitan area of Guadalajara.

All patients who meet the selection criteria and who sign their informed consent will be given the clinical history, as well as anthropometric and laboratory determinations. Once these values are known, the intervention will proceed with the research product, extract of green tea 400 mg twice a day or placebo 400 mg twice a day, this will be according to the technique of masking by the closed envelope technique for 12 weeks. Patients will be evaluated at 30, 60 and 90 days of intervention, for attachment assessment, tolerability of treatment, side effects and laboratory safety determinations. At the end of the 12 weeks of the intervention, the anthropometric and laboratory determinations will be made again as well as the determination of soluble RAGE by means of Elisa sandwich type, in serum obtained at the beginning and at 12 weeks of intervention.

The database will be developed in the statistical program Statistical software (SPSS) version 21.0. The qualitative variables will be expressed in frequencies and percentages, while the quantitative variables will be expressed in means and standard deviations, the normality test will be carried out through the Kolmogorov-Smirnov test and, according to the result, it will be decided for the analysis intra group perform paired t or Wilcoxon method and for intergroup t student or Mann-Whitney U. A value of p ≤0.05 will be considered statistically significant. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03622762
Study type Interventional
Source Centro Universitario de Ciencias de la Salud, Mexico
Contact Fernando Grover Páez, PhD
Phone (33) 10585200
Email fgroverp@hotmail.com
Status Recruiting
Phase Phase 2
Start date July 15, 2018
Completion date June 20, 2019

See also
  Status Clinical Trial Phase
Terminated NCT03840343 - Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease Phase 1
Completed NCT04549324 - Sleep Apnea, Coronary Atherosclerosis and Heart Failure in Diabetes Patients With Nephropathy
Recruiting NCT03502031 - Safety and Efficacy of Two Year of RAAS Alone or in Combination With Spironolactone Therapy Phase 4
Completed NCT03681704 - the Integrated Traditional Chinese and Western Medicine Treat Early Stage DKD Phase 1
Completed NCT03681249 - the Integrated Traditional Chinese and Western Medicine Treat Middle Stage DKD Early Phase 1
Withdrawn NCT03504566 - Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2) Phase 4
Completed NCT03889236 - Dietary Interventions on Glycocalyx Dimensions in South Asian Patients With Diabetic Nephropathy. N/A
Completed NCT06326034 - Impact of Dapagliflozin as Add-on Therapy on Glycemic Status and Quality of Life in Type 2 Diabetic Patients Phase 4
Recruiting NCT04931537 - Screening and Application Research of Early Diabetic Nephropathy Markers Based on Lipidomics.
Not yet recruiting NCT05373004 - Comparison Between the Efficacy of SGLT2 Inhibitor Therapy Versus ACE Inhibitor in the Treatment of Diabetic Kidney Disease Phase 2/Phase 3
Recruiting NCT03445247 - Extracorporeal Low-intensity Shockwave in Diabetic Nephropathy N/A
Not yet recruiting NCT06068439 - Study of the Protective Effect of Low-dose Aspirin on Renal Function in Patients With Early Diabetic Nephropathy Phase 2/Phase 3
Recruiting NCT04143412 - Efficacy of ACE Inhibitors, MRAs and ACE Inhibitor/ MRA Combination Phase 2
Not yet recruiting NCT06222476 - Effect of Dorzagliatin on Renal Function Outcomes in People With Type 2 Diabetes: a Multicentric, Prospective, Randomized Study. N/A
Completed NCT05487755 - Investigational and Comparative Study in the Management of Diabetic Nephropathy Phase 3
Active, not recruiting NCT04573920 - Atrasentan in Patients With Proteinuric Glomerular Diseases Phase 2
Recruiting NCT05888909 - Multidimensional Accurate Diagnosis and Treatment Technology and Clinical Transformation of Type 2 Diabetes Nephropathy
Not yet recruiting NCT04962399 - Relationship Between Serum N/OFQ and Type 2 Diabetic Nephropathy
Not yet recruiting NCT03591939 - T-regulatory Cells in Diabetic Type Two Nephropathy
Active, not recruiting NCT03859817 - Observational Study to Evaluate the Relationship Between Ketonemia and Renal Function in the Diabetic Patient